CAR-T therapy
The latest news about CAR-T therapy: headlines, AI summaries and the full story from every source.
- Caribou Biosciences to Discontinue CAR-T Programs and Explore Strategic Alternatives
- Cellectis Exits Two CAR-T Programs, Shifts Focus to Gene Editing for Lipid Disorders
- Bristol-Myers Squibb Outperforms Novartis Amid CAR-T Safety Concerns and Strong Financial Momentum
- Bristol-Myers Squibb Ends Partnership with Cellares, Raising Concerns About Breyanzi Manufacturing
- Cellectis Receives FDA RMAT Designation for Leukemia CAR-T Candidate Lasme-cel
- AvenCell Therapeutics Announces Phase 1a Results of CD123 CAR-T Therapy for AML at EHA 2026
- Legend Biotech Reports Strong CARVYKTI Sales Growth in Q1 2026
- Legend Biotech Stock Rises 18% on Analyst Upgrades and Eli Lilly's Acquisition
- Eli Lilly to Acquire Kelonia Therapeutics in $7 Billion Deal
- Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion